04:14:14 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Oncopeptides är ett läkemedelsbolag med störst specialiserings inom forskning och utveckling av cancerläkemedel. Sedan starten fokuserar bolaget främst på den egenutvecklade produkten Ygalo, en alkylerare för behandling av blodbaserade cancersjukdomar. Till kategorin räknas bland annat kronisk leukemi, lymfom och myelom. Bolaget är i utvecklingsfas där målet är att kommersialisera produkten i framtiden. Oncopeptides huvudkontor är beläget i Stockholm.

Kalender

2020-02-20 Bokslutskommuniké 2019
2019-12-17 Extra Bolagsstämma 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-07-12 Kvartalsrapport 2019-Q2
2019-05-22 Ordinarie utdelning ONCO 0.00 SEK
2019-05-21 Kvartalsrapport 2019-Q1
2019-05-21 Årsstämma 2018
2019-02-22 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-05-18 Ordinarie utdelning ONCO 0.00 SEK
2018-05-17 Årsstämma 2017
2018-05-17 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-15 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-18 Kvartalsrapport 2017-Q1
2017-05-18 Årsstämma 2016
2019-05-21 08:00:00

Summary of Q1

"The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides."

Financial overview January 1 - March 31, 2019 
  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 122.2 M (loss: 62.0)
  • Loss per share, before and after dilution, was SEK 2.57 (loss: 1.56)
  • On March 31 cash and cash equivalents amounted to SEK 747.5 M (664.9)
Significant events during the period January 1 - March 31, 2019 
  • In January, Oncopeptides completed a directed share issue of SEK 546.2 M (USD 60.0 M) before issue costs
  • At the end of March, data were presented at AACR annual meeting from Oncopeptides' clinical studies, HORIZON and ANCHOR, where melflufen is evaluated in multiple myeloma patients
Significant events after the reporting period 
  • In April, melflufen was granted additional patent protection in the US until 2033
  • In April it was announced that the last patient in the OCEAN trial is estimated to be enrolled during Q1 2020
  • In May it was announced that Oncopeptides will apply for Accelerated Approval in the US

Financial overview of the group

SEK thousand  2019 2018 2018
 Jan - Mar  Jan - Mar  Jan - Dec
Net sales - - -
Operating loss -121,934 -62,032 -419,300
Loss before tax -122,068 -62,032 -419,302
Loss for the period -122,199 -62,032 -419,449
Earnings per share before -2.57 -1.56 -9.77
and after dilution (SEK)
Cash flow from operating -142,821 -40,547 -333,727
activities
Cash and cash equivalents 747,471 664,944 375,617
at the end of the period
Research & development 78% 91% 77%
costs/operating expenses
%

Conference call for investors, analysts and the media
Oncopeptides will host a conference call and present an operational update on Tuesday May 21, at 10:00 (CET) 2019. It will be presented by CEO Jakob Lindberg and members of Oncopeptides management team.
The conference call will also be streamed via a link on the website: www.oncopeptides.com.

Phone numbers for participants from: 
Sweden:         +46 8 505 583 65
Europe:          +44 3333 009 035
USA:              +1 833 526 83 81

Financial calendar
Annual General Meeting 2019:  May 21, 2019
Interim Report Q2, 2019:          August 28, 2019
Interim Report Q3, 2019:          November 19, 2019
Year-end Report 2019:             February 20, 2020

For further information
Jakob Lindberg, CEO, Oncopeptides AB
E-mail: jakob.lindberg@oncopeptides.com
Telephone: +46 (0)8 615 20 40

Rein Piir, Head of Investor Relations, Oncopeptides AB
E-mail: rein.piir@oncopeptides.com
Telephone: +46 (0)70 853 72 92

This information is information that Oncopeptides is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on May 21, 2019. 

About Oncopeptides
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide-conjugated alkylator, belon­ging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in a global pivotal phase 3 trial called OCEAN, a phase 2 trial called HORIZON and in two additional supporting clinical trials. Oncopeptides' headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stock­holm with the ticker ONCO.